Companies /Healthcare

Tarsus Pharmaceuticals Inc

NASDAQ: TARS Biotechnology
$78.65
▼ $1.63 (−2.03%) today
Markets open · 10:13am ET

TARS at a Glance

Valuation
Market cap
$4.0B
Profitability
Revenue (TTM)
$682.2M
Profit margin
-102.9%
EPS (TTM)
$-15.86
Price
52-week range
$54 – $92
Street target
$103.44

Headquartered in Irvine, CA Fiscal year ends December NASDAQ: TARS tarsusrx.com

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused initially on eye care, with programs also spanning dermatology and infectious disease prevention. Its marketed product, XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly TP-03, is the first and only FDA-approved treatment for Demodex blepharitis. The drug works by eradicating Demodex mites through selective inhibition of parasite-specific GABA-Cl channels. The company sells XDEMVY in the United States through eye care professionals, supported by direct-to-consumer advertising and patient support programs. It also earns milestone revenue from a China out-license partner. Its development pipeline includes TP-04, a lotilaner gel for ocular rosacea (Phase 2 Kore), and TP-05, an oral lotilaner tablet designed to kill ticks and potentially prevent Lyme disease (Phase 2 Calliope). Through its 2026 acquisitions of iRenix Medical and Alkeus Pharmaceuticals, it added IRX-101, a chlorine dioxide-based ocular antiseptic for patients receiving intravitreal injections (Phase 3 planned). It also added gildeuretinol, a once-daily oral small molecule targeting vitamin A dimerization for Stargardt disease (Phase 3 Northstar). Updated

Latest Activity

TARSTarsus Pharmaceuticals
Q3 2026
EPS
-$14.40
est -$1.77-713.6%
Revenue
$195M
est $192M+1.5%

The loss per share is an accounting artifact: $632.2 million of acquired in-process R&D from the iRenix and Alkeus deals ran straight through the income statement. Underneath it, XDEMVY sales grew about 64% year over year, exceeding expectations on revenue. Management points to five medicines in five years, with no formal guidance.

Quarterly EPS — reported vs estimate

TARS Coverage

Frequently Asked Questions

What does Tarsus Pharmaceuticals do?

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused initially on eye care, with programs also spanning dermatology and infectious disease prevention.

What is the TARS stock price target?

The Wall Street consensus 12-month price target for TARS is $103.44.